Tocilizumab Cannot Prevent the Development of Bronchiolitis Obliterans in Patients with Castleman Disease–Associated Paraneoplastic Pemphigus

Liyang Gu,Shuang Ye
DOI: https://doi.org/10.1097/rhu.0000000000000675
2018-01-01
Journal of Clinical Rheumatology
Abstract:To the Editor: Paraneoplastic pemphigus (PNP) is a rare immune-mediated disease that is associated with underlying malignancy. Previous study revealed that approximately 15% of PNP cases are caused by Castleman disease (CD),1 a lymphoproliferative disorder, whereas in Chinese PNP patients, the number is much higher at approximately 50%. A recent large single-center report on Chinese CD patients (n = 114) indicated that one-third of them were initially presented as PNP.2 This further strengthened the link between PNP and CD among Chinese patients. Here, we report 2 consecutive cases who presented with refractory painful oral and genital mucosal lesions, which were suspected as having Behçet disease and were referred to our institution (Table 1). Mucosal biopsy confirmed pemphigus in the 2 cases, and further evaluation revealed mass lesions located at the mediastinum and retroperitoneum, respectively. The diagnoses of CD-associated PNP were established after surgical removal and pathology investigation of the mass (the pulmonary functions were normal according to the preoperative evaluation in both cases). Despite surgery plus high-dose prednisone and intravenous immunoglobulin, the PNP symptoms persisted.TABLE 1: Clinical Findings and Therapy Modalities in the 2 PatientsThe presence of PNP is known to be the most significant adverse prognostic factor among CD patients, with a 3-year mortality of greater than 40% as opposed to 12% among those without PNP.2 because interleukin 6 plays a fundamental role in the pathogenesis of CD,3 anti–interleukin 6 therapies (tocilizumab and siltuximab) have been implicated and displayed efficacy in multicentric CD.4 Tocilizumab and, lately, siltuximab5 have been approved for multicentric CD in Japan and North America, respectively. A case report has also demonstrated positive response to tocilizumab in a patient with CD-associated PNP.6 After discussion and informed consent was obtained, both our patients received monthly intravenous tocilizumab treatment. The mucosal lesions were significantly improved within 3 months with a rapid tapering of prednisone. However, this was unfortunately not a happy ending; both patients developed progressive dyspnea on exertion 6 to 10 months later. Bronchiolitis obliterans (BO) was confirmed in both cases according to pulmonary function test and high-resolution computed tomography scan. Tocilizumab was stopped, and patient 1 was eligible for referral to a lung transplantation institute. Bronchiolitis obliterans is a well-conceived severe complication that may occur in 30% of CD-associated PNP patients,2 even if the mass was removed after surgery. It was thought to be relevant to the autoantibodies' cross reaction against desmoplakin and respiratory epithelium proteins.7 Bronchiolitis obliterans incurs the worst outcome and usually leaves lung transplantation as the last option.8 The development of BO in CD-associated PNP, according to our 2 cases, apparently cannot be prevented, if not induced, by tocilizumab. Liyang Gu, MMShuang Ye, MD Department of Rheumatology Ren Ji Hospital South Campus Shanghai Jiaotong University School of Medicine, Shanghai People's Republic of China [email protected]
What problem does this paper attempt to address?